This MedLibrary.org supplementary page on Shire Pharmaceuticals is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
 |
|
| Type | Public (LSE: SHP) (NASDAQ: SHPGY) (TSX:SHPGY-Q) |
|---|---|
| Founded | 1986 |
| Headquarters | Basingstoke, England, UK |
| Key people | James Cavanaugh, Chairman Angus Russell, CEO |
| Industry | Pharmaceuticals |
| Revenue | $2,436 million (2007) |
| Operating income | $(1,379) million (2007) |
| Net income | $(1,451) million (2007) |
| Website | www.shire.com |
Shire plc (LSE: SHP), (NASDAQ: SHPGY), (TSX:SHPGY-Q) is a British manufacturer of pharmaceuticals including Adderall XR, Carbatrol, Fosrenol, and the recently released Vyvanse.
Contents |
History
Shire was founded by Harry Stratford and James Murray in 1986.[1] It was first listed on the London Stock Exchange in 1996[1] and in 1997 it went on to acquire Parmavene and Richmond Pharmaceutical Company.[1] In 2007 it acquired New River Pharmaceuticals Inc, a leading US drug maker, for $2.3bn.[2]
Operations
The Company seeks to develop and market products within advanced biotechnology for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.
The Company focuses its drug research and development on the relatively common mental abnormality Attention Deficit Hyperactivity Disorder (ADHD), as is made evident by the fact that three of its currently leading medications (Adderall/Adderall XR, Daytrana, and the newly developed Vyvanse), are intended for that disorder. However the Company also works on gastrointestinal (GI) treatments, human genetic therapies (HGT) and renal diseases.
Key products are as follows:[3]
ADHD
- Adderall XR: All age Attention Deficit Hyperactivity Disorder
- Daytrana: Pediatric Attention Deficit Hyperactivity Disorder
- Vyvanse: All age Attention Deficit Hyperactivity Disorder
Gastrointestinal
Human Genetic Therapies
- Elaprase: Hunter Syndrome
- Replagal: Fabry's disease
Renal
- Fosrenol: Hyperphosphatemia associated with End-Stage Renal Disease
- Dynepo: Anemia associated with End-Stage Renal Disease
Other
- Carbatrol: Epilepsy
- Reminyl (also sold as Razadyne): Alzheimer's Disease
- Xagrid (sold as Agrylin in the U.S.): Essential Thrombocytosis
Locations
The corporate offices are located in Basingstoke, Hampshire, UK. Other major offices are located in the United States in Wayne, Pennsylvania and Cambridge, Massachusetts. In addition, Shire owns a manufacturing site in Owings Mills, Maryland. The company has recently announced that it will move its tax domicile to Ireland.[4] The move will be effected through the creation of a new holding company in Jersey, which will pay reduced tax on global earnings in Ireland. The new structure is thought to be motivated mainly by the rule that royalties on patents lodged in Ireland are tax free.
Corporate leadership
The non-executive Board Chairman is Dr. James Cavanaugh. Matthew Emmens is the Chief Executive Officer and Chairman of the Executive Committee. The President of the Human Genetic Therapies division is Sylvie Gregoire and Mike Cola is the President of Specialty Pharmaceuticals.
References
External links
Wikipedia content modification information:
- This page was last modified on 18 September 2008, at 21:00.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Shire Pharmaceuticals".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.